

## ANALYSIS OF BIOCHEMICAL MARKERS IN DIABETIC AND NON-DIABETIC ACUTE MYOCARDIAL INFARCTION PATIENTS: A COMPARATIVE STUDY

Sushil Kumar<sup>1</sup>, Jaya Jain<sup>2</sup>, Kamna Singh<sup>3</sup>, Pavan Gautam<sup>3</sup>

Received : 12/05/2023  
Received in revised form : 15/07/2023  
Accepted : 25/08/2023

**Keywords:**

Acute Myocardial Infarction, Type 2 Diabetes Glutathione, Creatine Phosphokinase & CRP.

Corresponding Author:

**Dr. Pavan Gautam,**

Email: gautampavan009@gmail.com

DOI: 10.47009/jamp.2023.5.5.3

Source of Support: Nil,

Conflict of Interest: None declared

*Int J Acad Med Pharm*  
2023; 5(5); 11-14



<sup>1</sup>Ph.D. Scholar, Department of Biochemistry, Index Medical College, Hospital & Research Centre, Malwanchal University, Indore, Madhya Pradesh, India

<sup>2</sup>Associate professor, Department of Biochemistry, Index Medical College, Hospital & Research Centre, Malwanchal University, Indore, Madhya Pradesh, India

<sup>3</sup>Associate Professor, Department of Biochemistry, S.N. Medical College, Agra, Uttar Pradesh, India

### Abstract

**Background:** Diabetes is a metabolic condition that causes more free radicals to be produced, which causes oxidative stress. The purpose of this study was to compare the activity of cardiac and antioxidant enzymes in acute myocardial infarction (AMI) patients with and without diabetes. **Materials and Methods:** This cross-sectional study was conducted in the Department of Biochemistry, Index Institute of Medical Sciences and Hospital, Indore, Madhya Pradesh. There were 300 participants in this study, of whom 100 had normal blood glucose levels and normal ECGs (Normal, N), 100 had normal blood glucose levels and an AMI (Non-diabetic and AMI, N-AMI), and 100 had diabetes and an AMI (Diabetic and AMI, D-AMI). **Result:** Compared to N-AMI patients, D-AMI persons exhibited higher levels of TC, TG, LDL, and lower levels of HDL. According to a study, myocardial infarction patients with diabetes mellitus (DM) had significantly higher levels of cardiac markers such Troponin I, CPK, CK-MB, AST, LDH, and CRP than myocardial infarction patients without DM. Patients with D-AMI had lower levels of antioxidant SOD and GSH activity than those with N-AMI. MDA and CAT levels, however, were greater in D-AMI than in N-AMI controls. **Conclusion:** According to a study, D-AMI patients had lower antioxidant levels than N-AMI patients and have increased cardiac markers.

## INTRODUCTION

Diabetes mellitus raises the risk of CVD-induced mortality and the incidence of cardiovascular illnesses in diabetic persons compared to non-diabetic subjects.<sup>[1]</sup> The majority of deaths worldwide were caused by myocardial infarction and heart failure, which were caused by coronary artery disease.<sup>[2]</sup> The development of reactive oxygen species, myocardial ischemia leading to myocardial necrosis, and coronary artery obstruction are all factors in acute myocardial infarction.<sup>[3]</sup> According to earlier research, hyperglycemia increases the risk of heart problems caused by reactive oxygen species by interacting with lipids, proteins, and DNA,<sup>[4]</sup> myocardial antioxidants can reverse this oxidative damage.<sup>[5]</sup> Numerous studies have shown that antioxidant function is reduced in diabetic subjects,<sup>[6]</sup> which may contribute to the pathogenesis of acute myocardial infarction caused by oxidative stress.<sup>[7]</sup> It is generally known that risk factors for the development of acute myocardial

infarction include smoking, diabetes, dyslipidemia, hypertension, family history, obesity, and hypertension.<sup>[8]</sup> The aim of the study was to evaluate whether diabetic and non-diabetic acute myocardial infarction patients had cardiac damage brought on by oxidative stress. This study emphasises that, along with other signs like the ECG and cardiac biomarkers, an imbalance in antioxidants may be a crucial sign of diabetes-related myocardial damage.

## MATERIALS AND METHODS

This cross-sectional study was conducted in the Department of Biochemistry, Index Institute of Medical Sciences and Hospital, Indore, Madhya Pradesh. This present study included 300 subjects, and categories in to three groups: Group-1: 100 subjects were with normal blood glucose level and with normal ECG (Normal, N), Group-2: 100 subjects were with normal blood glucose level and AMI (Non-diabetic and AMI, N-AMI) and Group-3: 100 subjects were with diabetes and AMI (Diabetic

and AMI, D-AMI). Analysing the level of glycated haemoglobin (HbA1c>6.5%) allowed for the diagnosis of diabetes. After receiving written permission to participate from their carers, diagnosed cases of both diabetic and non-diabetic AMI patients were included in the study. Patients' biographical information, a thorough medical history, blood pressure readings, and electrocardiograms (ECG) were duly entered into questionnaires.

#### Inclusion and Exclusion Criteria

There were both male and female subjects having a history of AMI. Chest discomfort history, ECG abnormalities, and increased cardiac enzymes were used to diagnose AMI. This study covered both diabetic and non-diabetic AMI patients. The control subjects were chosen because they had a normal ECG and were not hypertensive. The study did not include participants with histories of smoking, obesity, or any other ailment.

#### Data Collection

All individuals had their cubital veins used to collect blood samples, which were then separated into serum and immediately transported in an icebox from the hospital to the lab. At 4°C, blood samples were centrifuged for 10 minutes at 2100 x g. In order to store the serum for examination at -20°C, it was aspirated.

#### Evaluation of Cardiovascular Parameters

Using commercial test kits, the concentrations of TC, TG, and HDL in the blood were determined spectrophotometrically. Using the Friedewald formula, LDL was determined.<sup>[9]</sup>

#### Analysis of Cardiac Markers

Using commercially available kits, the levels of several cardiac enzymes, including troponin-I(TnI), CPK, CK-MB, LDH, AST, and CRP, were measured.

#### Estimation of Oxidative Stress

Using commercial kits, the serum concentrations of MDA, CAT, SOD, and GSH were examined to determine the level of oxidative stress.

#### Statistical Analysis


Software called Epi-info was used to do the statistical analysis. Three sets of quantitative variables were initially compared using one-way ANOVA, and the locations of the differences between the groups were then confirmed using the

Bonferroni post hoc test. The means and standard deviations (SD) for all the data were displayed. Statistics were judged significant at P <0.05.

## RESULTS

This study covered 300 patients in total. Three sets of study participants were used: group A (Control) consisted of healthy persons, group B (N-AMI) of AMI patients, and group C (D-AMI) of patients with both diabetes mellitus and AMI. In all three groups, the distribution of participants by age is shown in [Table 1].

In all groups, the average age and sex were comparable. In [Table2], D-AMI and N-AMI had higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) than the normal group. When compared to the N-AMI and normal groups in [Table 3], the fasting blood glucose, postprandial blood glucose, and HbA1c values in the D-AMI group were all considerably higher (P 0.001).



**Figure 1: Shows the level of fasting and postprandial blood sugar in different groups.**

The TC (274.65±21.24), TG (306.32±54.36), and LDL (294.32±24.36) levels in the D-AMI group were significantly higher than those in the N-AMI group for the corresponding values of TC (238.34±16.54), TG (232.21±20.14), and LDL (249.32±32.14). While N-AMI group had significantly higher levels of HDL (31.54±5.32) and N group had 41.21±7.38 correspondingly, D-AMI group had significantly lower levels (27.65±4.21). [Table 4]

**Table 1: Distribution of subjects according to age group.**

| Age group | Control      | N-AMI       | D-AMI        |
|-----------|--------------|-------------|--------------|
| 35-50     | 32 (32.0%)   | 37 (37.0%)  | 36 (36.0%)   |
| 50-65     | 68 (68.0%)   | 63 (63.0%)  | 64 (64.0%)   |
| Total     | 100 (100.0%) | 100(100.0%) | 100 (100.0%) |

**Table 2: Shows the general demographic characteristics.**

| Variables       | Control      | N-AMI        | D-AMI        | P value |
|-----------------|--------------|--------------|--------------|---------|
| Male : Female   | 64:36        | 67:33        | 62:38        | 0.25    |
| Age in years    | 50.24±14.21  | 51.26±15.34  | 51.76±15.36  | 0.18    |
| SPB in mm of Hg | 122.14±26.04 | 134.23±28.54 | 150.32±31.25 | 0.01    |
| DBP in mm of Hg | 80.54±16.21  | 86.32±17.54  | 98.21±18.26  | 0.01    |

**Table3: Shows the comparison of sugar profile.**

| Sugar profile | Control      | N-AMI        | D-AMI        | P value |
|---------------|--------------|--------------|--------------|---------|
| FBS (mg/dl)   | 88.28±15.25  | 96.84±25.34  | 178.45±32.32 | 0.01    |
| PPBS (mg/dl)  | 121.18±25.06 | 128.54±27.21 | 215.54±45.26 | 0.01    |
| HbA1c (%)     | 4.41±1.32    | 4.54±1.56    | 7.39±2.54    | 0.001   |

**Table4: Shows the comparison of lipid profile.**

| Lipid profile          | Control      | N-AMI        | D-AMI        | P value |
|------------------------|--------------|--------------|--------------|---------|
| T. cholesterol (mg/dl) | 184.45±14.21 | 238.34±16.54 | 274.65±21.24 | 0.001   |
| Triglycerides (mg/dl)  | 152.21±15.32 | 232.21±20.14 | 306.32±54.36 | 0.001   |
| HDL-c (mg/dl)          | 41.21±7.38   | 31.54±5.32   | 27.65±4.21   | 0.03    |
| LDL-c (mg/dl)          | 138.24±14.65 | 249.32±32.14 | 294.32±24.36 | 0.001   |

**Table 5: Shows the comparison of cardiac profile.**

| Cardiac profile    | Control      | N-AMI        | D-AMI         | P value |
|--------------------|--------------|--------------|---------------|---------|
| Troponin I (ng/ml) | 0.96±0.36    | 1.86±0.21    | 3.35±0.38     | 0.01    |
| CPK IU/L           | 131.21±16.35 | 342.54±26.54 | 1078.04±45.68 | 0.01    |
| CPK-MB (IU/L)      | 43.21±8.32   | 109.26±12.56 | 244.28±18.24  | 0.01    |
| LDH (IU/L)         | 112.36±15.42 | 614.32±48.36 | 1008.2±54.62  | 0.01    |
| CRP (mg/L)         | 1.26±0.52    | 4.58±1.24    | 7.94±2.54     | 0.01    |
| SGOT (IU/L)        | 22.42±6.20   | 64.34±9.21   | 101.6.2±23.52 | 0.01    |

**Table 6: Shows the comparison of oxidative stress.**

| Oxidative stress variables | Control     | N-AMI       | D-AMI      | P value |
|----------------------------|-------------|-------------|------------|---------|
| MDA (nmol/ml)              | 0.05±0.002  | 0.06±0.0021 | 0.9±0.013  | 0.01    |
| CAT (MU/L)                 | 1.05±0.035  | 0.85±0.008  | 0.92±0.041 | 0.01    |
| SOD (units/ml)             | 0.087±0.004 | 0.061±0.01  | 0.055±0.02 | 0.01    |
| GSH (µM)                   | 0.11±0.004  | 0.06±0.002  | 0.05±0.002 | 0.01    |

## DISCUSSION

Due to increased ROS production,<sup>[10]</sup> activation of pro-inflammatory responses,<sup>[11]</sup> decreased antioxidant activity,<sup>[12]</sup> increased lipid peroxidation, and myocardial ischemia,<sup>[10]</sup> AMI is brought on. All of these incidents cause plaque to become activated, coronary blockages to form, and ultimately heart attacks. AMI affects a significant portion of the population.<sup>[13]</sup> Many risk factors, including diabetes, dyslipidemia, hypertension, smoking, obesity, and advancing age, are connected to the emergence of AMI.<sup>[14]</sup> According to Bartels et al.'s research,<sup>[15]</sup> those with diabetes have a higher chance of developing CVD than people without the condition. The current investigation discovered the impact of diabetes, hypertension, and dyslipidemia in D-AMI patients. It has been discovered that type 2 diabetes alters the way lipids and lipoproteins are used and causes atherogenic dyslipidemia.<sup>[16]</sup> Our findings indicate that D-AMI patients had significantly lower levels of HDL while significantly higher levels of TC, TG, and LDL. This shows that atherogenic dyslipidemia plays a significant role in the development of AMI in diabetic people. Inducing both local and systemic inflammatory reactions, atherogenic dyslipidemia favours the oxidative alteration of proteins along with lipids, especially LDL.<sup>[17]</sup> By detecting the CRP level, cardiac tissue harm brought on by these inflammatory reactions can be identified. In fact, CRP is a marker of systemic inflammation and provides predictive data for cardiovascular events like CAD and atherosclerosis.<sup>[18]</sup> In this study, D-AMI patients' CRP levels were higher than those of N-AMI

patients. By assessing the myocardial tissue-specific protein Trop I, which is involved in cardiac contractility, heart contractility is assessed. Previous research suggested that the myocardial damage marker Trop I is extremely sensitive and specific, making it a useful diagnostic tool for AMI.<sup>[19]</sup> This study demonstrated that D-AMI patients had considerably higher levels of Trop I than N-AMI patients, indicating that diabetic persons have a higher rate of cardiac muscle cell death. CPK and CPK-MB are two crucial markers of myocardial necrosis,<sup>[20]</sup> and this study's D-AMI group had significantly elevated levels of both markers. Additionally, we discovered a statistically significant difference in LDH and AST values between the D-AMI and N-AMI groups, the two indicators that have previously been recommended for the diagnosis of infarct. It has been suggested that oxidative stress brought on by hyperlipidemia and hyperglycemia contributes to the development of AMI.<sup>[2]</sup> The disruption between free radicals and antioxidant defence mechanisms is brought on by oxidative stress. Superoxide radicals are broken down into oxygen or hydrogen peroxide by SOD, one of the vital defence enzymes.<sup>[21]</sup> Glutathione peroxidase, often known as CAT, catalyses the conversion of hydrogen peroxide into water; GPX, on the other hand, depends on reduced glutathione for this reaction.<sup>[22]</sup> Additionally, GSH prevents lipid peroxidation. Previous studies indicated that lipid peroxidation increased in AMI patients,<sup>[23]</sup> and that this enhanced lipoperoxidation is a result of the oxidative stress caused by hyperglycemia.

## CONCLUSION

The research we performed demonstrates the importance of atherosclerosis and its related consequences in D-AMI patients, including dyslipidemia and inflammation. In conclusion, our research shows that D-AMI patients had significantly higher levels of non-traditional cardiac markers like CRP compared to NAMI patients as well as standard cardiac markers including CPK, CK-MB, LDH, and AST. The study demonstrates that while levels of the antioxidants CAT, SOD, and GSH are decreased in D-AMI patients, the oxidative stress measure MDA significantly increases. Clinicians treating MI patients with DM will find these outcomes useful.

## REFERENCES

1. Kalofoutis C, Piperi C, Kalofoutis A, et al. Type II diabetes mellitus and cardiovascular risk factors: current therapeutic approaches. *Exp Clin Cardiol.* 2007;12:17–28.
2. Ezekowitz JA, Kaul P, Bakal JA, et al. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. *J Am Coll Cardiol.* 2009;53:13–20.
3. Kasap S, Gonenç A, Sener DE, Hisar I. Serum cardiac markers in patients with acute myocardial infarction: oxidative stress, C-reactive protein and N-terminal probrain natriuretic Peptide. *J Clin Biochem Nutr.* 2007;41:50–57.
4. Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. *Curr Pharm Des.* 2013;19:5695–5703.
5. Lu Z, Xu X, Hu X, et al. PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. *Antioxid Redox Signal.* 2010;13:1011–1022.
6. Jimenez-Osorio AS, Picazo A, Gonzalez-Reyes S, et al. Nrf2 and redox status in prediabetic and diabetic patients. *Int J Mol Sci.* 2014;15:20290–20305.
7. Di Filippo C, Cuzzocrea S, Rossi F, et al. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. *Cardiovasc Drug Rev.* 2006;24:77–87.
8. Boyer NM, Laskey WK, Cox M, et al. Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the American Heart Association get with the guidelines coronary artery disease program. *J Am Heart Assoc.* 2012;1:e001206.
9. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. *Clin Chem.* 1972;18:449–506
10. Surekha RH, Srikanth BB, Jharna P, et al. oxidative stress and total antioxidant status in myocardial infarction. *Singap Med J.* 2007;48:137-142.
11. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. *Am J Cardiol.* 2003;91:12A-16A.
12. Kazmi KA, Iqbal SP, Bakr A, Iqbal MP. Admission creatine kinase as a prognostic marker in acute myocardial infarction. *J Pak Med Assoc.* 2009;59:819-822.
13. faisal AW, Ayub M, Wassem T, et al. Risk factors in young patients of acute myocardial infarction. *J Ayub Med Coll Abbottabad.* 2011;23:10-13.
14. Whiting DR, Gauriguata L, Weil C, Shaw J. IDF. Diabetes Atlas. Global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract.* 2011;94:311-21.
15. Bartels DW, Davidson MH, Gong WC. Type 2 diabetes and cardiovascular disease: reducing the risk. *J Manag Care Pharm.* (2 suppl A):2007;(2 suppl A):S2-S15.
16. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. *Curr Atheroscler Rep.* 2007;9:162-168.
17. Stocker R, Kearney Jr JG. Role of oxidative modifications in atherosclerosis. *Physiol Rev.* 2004;84:1381-1478.
18. Calabro P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. *Semin Immunopathol.* 2009;31:79-94.
19. Tiwari RP, Jain A, Khan Z, et al. Cardiac troponins I and T: molecular markers for early diagnosis, prognosis and accurate triaging of patients with acute myocardial infarction. *Mol Diagn Ther.* 2012;16:371-381.
20. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardio.* 2000;36:959-969.
21. Maghamiour N, Safaie N. High creatine kinase and lactate dehydrogenase in the absence of myocardial injury or infarction: a case report. *J Cardiovasc Thorac Res.* 2014;6:69-70.
22. Rodrigo R, Libuy M, Feliu F, Hasson D. Oxidative stress-related biomarkers in essential hypertension and ischemiareperfusion myocardial damage. *Dis Markers.* 2013;35:773-790.
23. Aquilano K, Baldelli S, Ciriolo MR. Glutathione: new roles in redox signaling for an old antioxidant. *Front Pharmacol.* 2014;5:196.